These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 29393428)

  • 1. Integration of transcriptomics, proteomics, metabolomics and systems pharmacology data to reveal the therapeutic mechanism underlying Chinese herbal Bufei Yishen formula for the treatment of chronic obstructive pulmonary disease.
    Zhao P; Li J; Yang L; Li Y; Tian Y; Li S
    Mol Med Rep; 2018 Apr; 17(4):5247-5257. PubMed ID: 29393428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. System biology analysis of long-term effect and mechanism of Bufei Yishen on COPD revealed by system pharmacology and 3-omics profiling.
    Li J; Zhao P; Yang L; Li Y; Tian Y; Li S
    Sci Rep; 2016 May; 6():25492. PubMed ID: 27146975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining systems pharmacology, transcriptomics, proteomics, and metabolomics to dissect the therapeutic mechanism of Chinese herbal Bufei Jianpi formula for application to COPD.
    Zhao P; Yang L; Li J; Li Y; Tian Y; Li S
    Int J Chron Obstruct Pulmon Dis; 2016; 11():553-66. PubMed ID: 27042044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating Transcriptomics, Proteomics, and Metabolomics Profiling with System Pharmacology for the Delineation of Long-Term Therapeutic Mechanisms of Bufei Jianpi Formula in Treating COPD.
    Zhao P; Li J; Li Y; Tian Y; Yang L; Li S
    Biomed Res Int; 2017; 2017():7091087. PubMed ID: 28424787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective-component compatibility of Bufei Yishen formula II inhibits mucus hypersecretion of chronic obstructive pulmonary disease rats by regulating EGFR/PI3K/mTOR signaling.
    Li J; Ma J; Tian Y; Zhao P; Liu X; Dong H; Zheng W; Feng S; Zhang L; Wu M; Zhu L; Liu S; Zhao D
    J Ethnopharmacol; 2020 Jul; 257():112796. PubMed ID: 32344236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease.
    Li J; Zhao P; Li Y; Tian Y; Wang Y
    Sci Rep; 2015 Oct; 5():15290. PubMed ID: 26469778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoring Th17/Treg balance via modulation of STAT3 and STAT5 activation contributes to the amelioration of chronic obstructive pulmonary disease by Bufei Yishen formula.
    Zhao P; Li J; Tian Y; Mao J; Liu X; Feng S; Li J; Bian Q; Ji H; Zhang L
    J Ethnopharmacol; 2018 May; 217():152-162. PubMed ID: 29454913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated serum metabolomics and network pharmacology analysis on the bioactive metabolites and mechanism exploration of Bufei huoxue capsule on chronic obstructive pulmonary disease rats.
    Ren H; Wu W; Chen J; Li Q; Wang H; Qian D; Guo S; Duan JA
    J Ethnopharmacol; 2024 Apr; 324():117816. PubMed ID: 38286154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective-constituent compatibility-based analysis of Bufei Yishen formula, a traditional herbal compound as an effective treatment for chronic obstructive pulmonary disease.
    Li JS; Liu XF; Dong HR; Zheng WC; Feng SX; Tian YG; Zhao P; Ma JD; Ren ZX; Xie Y
    J Integr Med; 2020 Jul; 18(4):351-362. PubMed ID: 32565294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A chinese herbal formula ameliorates COPD by inhibiting the inflammatory response via downregulation of p65, JNK, and p38.
    Li J; Xie Y; Zhao P; Qin Y; Oliver BG; Tian Y; Li S; Wang M; Liu X
    Phytomedicine; 2021 Mar; 83():153475. PubMed ID: 33545548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomics study on model rats of chronic obstructive pulmonary disease treated with Bu‑Fei Jian‑Pi.
    Li J; Yang L; Li Y; Tian Y; Li S; Jiang S; Wang Y; Li X
    Mol Med Rep; 2015 Feb; 11(2):1324-33. PubMed ID: 25370181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systems pharmacology-based approach for dissecting the active ingredients and potential targets of the Chinese herbal Bufei Jianpi formula for the treatment of COPD.
    Zhao P; Li J; Li Y; Tian Y; Wang Y; Zheng C
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2633-56. PubMed ID: 26674991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating 3-omics data analyze rat lung tissue of COPD states and medical intervention by delineation of molecular and pathway alterations.
    Li J; Zhao P; Yang L; Li Y; Tian Y; Li S; Bai Y
    Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28450497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective-component compatibility of Bufei Yishen formula alleviates chronic obstructive pulmonary disease inflammation by regulating GSK3β-mediated NLRP3 inflammasome activation.
    Qin Y; Zhai J; Yang J; Li H; Tian Y; Liu X; Zhao P; Li J
    Biomed Pharmacother; 2023 Dec; 168():115614. PubMed ID: 37862971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bufei Yishen granules combined with acupoint sticking therapy suppress oxidative stress in chronic obstructive pulmonary disease rats: Via regulating peroxisome proliferator-activated receptor-gamma signaling.
    Li Y; Tian YG; Li JS; Dong YQ; Wang MH; Feng SX; Li LL; Mao J; Wang LL; Luo S
    J Ethnopharmacol; 2016 Dec; 193():354-361. PubMed ID: 27562320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of three Tiao-Bu Fei-Shen therapies on NF-κB/TGF-β1/smad2 signaling in rats with chronic obstructive pulmonary disease.
    Li Y; Li JS; Li WW; Li SY; Tian YG; Lu XF; Jiang SL; Wang Y
    BMC Complement Altern Med; 2014 Apr; 14():140. PubMed ID: 24766819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Compatibility characteristics of Bufei Yishen formula III in regulating chronic obstructive pulmonary disease mucus hypersecretion].
    Qin Y; Li M; Tian Y; Zhao P; Li K; Li C; Li J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Nov; 33(11):1309-1314. PubMed ID: 34980299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective-component compatibility of Bufei Yishen formula III ameliorated COPD by improving airway epithelial cell senescence by promoting mitophagy via the NRF2/PINK1 pathway.
    Li MY; Qin YQ; Tian YG; Li KC; Oliver BG; Liu XF; Zhao P; Li JS
    BMC Pulm Med; 2022 Nov; 22(1):434. PubMed ID: 36414945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bufei Yishen Formula Restores Th17/Treg Balance and Attenuates Chronic Obstructive Pulmonary Disease
    Zhao P; Liu X; Dong H; Tian Y; Feng S; Zhao D; Ren Z; Zhang L; Li J
    Front Pharmacol; 2020; 11():1212. PubMed ID: 32848801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bufei Yishen Formula Inhibits the Cell Senescence in COPD by Up-Regulating the ZNF263 and Klotho Expression.
    Wang W; Zhang S; Cui L; Chen Y; Xu X; Wu L
    Int J Chron Obstruct Pulmon Dis; 2023; 18():533-539. PubMed ID: 37065635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.